Resources from the same session
381O - First-in-human/phase I trial of HS-20089, a B7-H4 ADC, in patients with advanced solid tumors
Presenter: Jian Zhang
Session: Proffered Paper session - Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
376O - Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Updated survival results of the randomized, phase III DESTINY-Breast04 study
Presenter: Shanu Modi
Session: Proffered Paper session - Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
Invited Discussant 381O and 376O
Presenter: Giampaolo Bianchini
Session: Proffered Paper session - Breast cancer, metastatic
Resources:
Slides
Webcast
Q&A
Presenter: All Speakers
Session: Proffered Paper session - Breast cancer, metastatic
Resources:
Webcast
377O - A pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) with brain metastases (BMs) from DESTINY-Breast (DB) -01, -02, and -03
Presenter: Sara Hurvitz
Session: Proffered Paper session - Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
378O - Persistence under abemaciclib and endocrine treatment (ABA+ET) in patients with advanced breast cancer (aBC): First results of the randomized IMPACT trial comparing patient coaching with the MASCC oral agent teaching tool (MOATT) versus local routine patient coaching (LC)
Presenter: Manfred Welslau
Session: Proffered Paper session - Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
Invited Discussant 377O and 378O
Presenter: Janice Wing-Hang Tsang
Session: Proffered Paper session - Breast cancer, metastatic
Resources:
Slides
Webcast